Glycoform-resolved FcɣRIIIa affinity chromatography–mass spectrometry

References

• Jiang XR, Song A, Bergelson S, Arroll T, Parekh B, May K, Chung S, Strouse R, Mire-Sluis A, Schenerman M. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov. 2011;10:101–11. doi:10.1038/nrd3365.
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. Fcγ receptors as regulators of immune responses. Nat Rev Immunol. 2008;8:34–47. doi:10.1038/nri2206.
   PubMed Web of Science ®Google Scholar
• Shields RL, Lai J, Keck R, O’Connell LY, Hong K, Meng YG, Weikert SH, Presta LG. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity. J Biol Chem. 2002;277:26733–40. doi:10.1074/jbc.M202069200.
   PubMed Web of Science ®Google Scholar
• Ferrara C, Grau S, Jäger C, Sondermann P, Brünker P, Waldhauer I, Hennig M, Ruf A, Rufer AC, Stihle M, et al. Unique carbohydrate–carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose. Proc Natl Acad Sci USA. 2011;108:12669–74. doi:10.1073/pnas.1108455108.
   PubMed Web of Science ®Google Scholar
• Beck A, Reichert JM. Marketing approval of mogamulizumab: a triumph for glyco-engineering. mAbs. 2012;4:419–25. doi:10.4161/mabs.20996.
   PubMed Web of Science ®Google Scholar
• Evans JB, Syed BA. Next-generation antibodies. Nat Rev Drug Discov. 2014;13:413–14. doi:10.1038/nrd4255.
   PubMed Web of Science ®Google Scholar
• Dekkers G, Treffers L, Plomp R, Bentlage AEH, de Boer M, Koeleman CAM, Lissenberg-Thunnissen SN, Visser R, Brouwer M, Mok JY, et al. Decoding the human immunoglobulin G-glycan repertoire reveals a spectrum of Fc-receptor- and complement-mediated-effector activities. Front Immunol. 2017;8. doi:10.3389/fimmu.2017.00877.
   PubMed Web of Science ®Google Scholar
• Thomann M, Schlothauer T, Dashivets T, Malik S, Avenal C, Bulau P, Rüger P, Reusch D, Chammas R. In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity. PLoS One. 2015;10:e0134949. doi:10.1371/journal.pone.0134949.
   PubMed Web of Science ®Google Scholar
• Reusch D, Tejada ML. Fc glycans of therapeutic antibodies as critical quality attributes. Glycobiology. 2015;25:1325–34. doi:10.1093/glycob/cwv065.
   PubMed Web of Science ®Google Scholar
• Cymer F, Beck H, Rohde A, Reusch D. Therapeutic monoclonal antibody N-glycosylation–structure, function and therapeutic potential. Biologicals. 2018;52:1–11. doi:10.1016/j.biologicals.2017.11.001.
   PubMed Web of Science ®Google Scholar
• Sondermann P, Huber R, Oosthuizen V, Jacob U. The 3.2-Å crystal structure of the human IgG1 Fc fragment–fcγRIII complex. Nature. 2000;406:267. doi:10.1038/35018508.
   PubMed Web of Science ®Google Scholar
• Wada R, Matsui M, Kawasaki N. Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms. mAbs. 2019;11:350–72. doi:10.1080/19420862.2018.1551044.
   PubMed Web of Science ®Google Scholar
• Dashivets T, Thomann M, Rueger P, Knaupp A, Buchner J, Schlothauer T, Karagiannis SN. Multi-angle effector function analysis of human monoclonal IgG glycovariants. PLoS One. 2015;10:e0143520. doi:10.1371/journal.pone.0143520.
   PubMed Web of Science ®Google Scholar
• Li H, Nguyen HH, Loo RRO, Campuzano IDG, Loo JA. An integrated native mass spectrometry and top-down proteomics method that connects sequence to structure and function of macromolecular complexes. Nat Chem. 2018;10:139–48. doi:10.1038/nchem.2908.
   PubMed Web of Science ®Google Scholar
• Rosati S, Yang Y, Barendregt A, Heck AJR. Detailed mass analysis of structural heterogeneity in monoclonal antibodies using native mass spectrometry. Nat Protoc. 2014;9:967–76. doi:10.1038/nprot.2014.057.
   PubMed Web of Science ®Google Scholar
• Bailey AO, Han G, Phung W, Gazis P, Sutton J, Josephs JL, Sandoval W. Charge variant native mass spectrometry benefits mass precision and dynamic range of monoclonal antibody intact mass analysis. mAbs. 2018;10:1214–25. doi:10.1080/19420862.2018.1521131.
   PubMed Web of Science ®Google Scholar
• Campuzano ID, Li H, Bagal D, Lippens JL, Svitel J, Kurzeja RJ, Xu H, Schnier PD, Loo JA. Native MS analysis of bacteriorhodopsin and an empty nanodisc by orthogonal acceleration time-of-flight, orbitrap and ion cyclotron resonance. Anal Chem. 2016;88:12427–36. doi:10.1021/acs.analchem.6b03762.
   PubMed Web of Science ®Google Scholar
• Gahoual R, Heidenreich A-K, Somsen GW, Bulau P, Reusch D, Wuhrer M, Haberger M. Detailed characterization of monoclonal antibody receptor interaction using affinity liquid chromatography hyphenated to native mass spectrometry. Anal Chem. 2017;89:5404–12. doi:10.1021/acs.analchem.7b00211.
   PubMed Web of Science ®Google Scholar
• Kiyoshi M, Caaveiro JM, Tada M, Tamura H, Tanaka T, Terao Y, Morante K, Harazono A, Hashii N, Shibata H, et al. Assessing the heterogeneity of the Fc-glycan of a therapeutic antibody using an engineered FcγReceptor IIIa-immobilized column. Sci Rep. 2018;8:3955. doi:10.1038/s41598-018-22199-8.
   PubMed Web of Science ®Google Scholar
• Patel KR, Roberts JT, Subedi GP, Barb AW. Restricted processing of CD16a/Fc γ receptor IIIa N-glycans from primary human NK cells impacts structure and function. J Biol Chem. 2018;293:3477–89. doi:10.1074/jbc.RA117.001207.
   PubMed Web of Science ®Google Scholar
• Washburn N, Meccariello R, Duffner J, Getchell K, Holte K, Prod’homme T, Srinivasan K, Prenovitz R, Lansing J, Capila I, et al. Characterization of endogenous human FcγRIII by mass spectrometry reveals site, allele and sequence specific glycosylation. Mol Cell Proteomics. 2019;18:534–45. doi:10.1074/mcp.RA118.001142.
   PubMed Web of Science ®Google Scholar
• Zeck A, Pohlentz G, Schlothauer T, Peter-Katalinić J, Regula J. Cell type-specific and site directed N-glycosylation pattern of FcγRIIIa. J Proteome Res. 2011;10:3031–39. doi:10.1021/pr1012653.
   PubMed Web of Science ®Google Scholar
• Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov. 2009;8:226–34. doi:10.1038/nrd2804.
   PubMed Web of Science ®Google Scholar
• Shatz W, Chung S, Li B, Marshall B, Tejada M, Phung W, Sandoval W, Kelley RF, Scheer JM. Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity. mAbs. 2013;5:872–81. doi:10.4161/mabs.26307.
   PubMed Web of Science ®Google Scholar
• Ferrara C, Brünker P, Suter T, Moser S, Püntener U, Umaña P. The carbohydrate at FcγRIIIa Asn-162: an element required for high affinity binding to non-fucosylated IgG glycoforms. Biotechnol Bioeng. 2006;93:851–61. doi:10.1074/jbc.M510171200.
   PubMed Web of Science ®Google Scholar
• Dekkers G, Plomp R, Koeleman CA, Visser R, Von Horsten HH, Sandig V, Rispens T, Wuhrer M, Vidarsson G. Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycans. Sci Rep. 2016;6:36964. doi:10.1038/srep36964.
   PubMed Web of Science ®Google Scholar
• Yu M, Brown D, Reed C, Chung S, Lutman J, Stefanich E, Wong A, Stephan J-P, Bayer R. Production, characterization and pharmacokinetic properties of antibodies with N-linked Mannose-5 glycans. mAbs. 2012;4:475–87. doi:10.4161/mabs.20737.
   PubMed Web of Science ®Google Scholar
• Liu YD, Flynn GC. Effect of high mannose glycan pairing on IgG antibody clearance. Biologicals. 2016;44:163–69. doi:10.1016/j.biologicals.2016.02.003.
   PubMed Web of Science ®Google Scholar
• Yang Y, Wang G, Song T, Lebrilla CB, Heck AJ. Resolving the micro-heterogeneity and structural integrity of monoclonal antibodies by hybrid mass spectrometric approaches. MAbs. 2017;9:638–45. doi:10.1080/19420862.2017.1290033.
   PubMed Web of Science ®Google Scholar
• Ha S, Ou Y, Vlasak J, Li Y, Wang S, Vo K, Du Y, Mach A, Fang Y, Zhang N. Isolation and characterization of IgG1 with asymmetrical Fc glycosylation. Glycobiology. 2011;21:1087–96. doi:10.1093/glycob/cwr047.
   PubMed Web of Science ®Google Scholar